Get the Daily Brief
Latest Biotech News
Nanoparticle IL‑12 therapy revives ovarian immunotherapy responses
MIT teams published preclinical data showing polymer‑coated nanoparticles that deliver IL‑12 directly to ovarian tumors can convert immunologically cold lesions into responsive ones and, when...
Gene therapy milestone for ADA‑SCID... Baby KJ roadmap published
A joint UCL–UCLA gene therapy program reported multi‑year follow‑up data showing a gene therapy for ADA‑SCID restored immune function in treated children with a 95% success rate and no major...
Metsera takeover fight: Novo tops Pfizer with higher bid, legal clash ensues
Novo Nordisk submitted a higher unsolicited offer for obesity biotech Metsera, prompting an immediate legal and strategic response from Pfizer. Novo’s bid raises the deal value well above Pfizer’s...
Intellia CRISPR trials halted: FDA places formal hold after liver toxicity case
The FDA placed a clinical hold on two Phase 3 trials of Intellia Therapeutics’ CRISPR candidate nexiguran ziclumeran after a participant experienced severe liver enzyme elevations and...
Human kidney organoids scaled and integrated into pig kidneys...first in‑vivo transplant milestone
Researchers developed a scalable method to produce thousands of human kidney organoids and demonstrated integration with perfused porcine kidneys ex vivo, culminating in the first transplant of...
AI accelerates drug discovery and cell modeling: Google proposes a cancer drug; CZI and NVIDIA scale virtual cells
Google unveiled an AI-led discovery claiming a validated new cancer drug combination generated by its Cell2Sentence-Scale model family, signaling rapid advances in foundation models applied to...
Heritable genome editing and bespoke CRISPR: startups form and clinicians publish FDA playbook
A wave of ventures pursuing heritable genome editing emerged, with one U.S. entrepreneur raising significant early funding to study the ethics and feasibility of gene-edited embryos. At the same...
Tumor resistance mechanisms: Myeloid IFNγ signaling and copy-number changes undermine immunotherapy
Dana-Farber researchers identified interferon‑gamma signaling within tumor-associated myeloid cells as a driver of resistance to immune checkpoint inhibitors in renal cell carcinoma, revealing a...
Localized cytokine delivery: IL‑12 nanoparticles revive ovarian tumor immunity in preclinical models
MIT and collaborators engineered polymer-coated nanoparticles that deliver IL‑12 directly to ovarian tumors and demonstrated robust antitumor responses when combined with checkpoint inhibitors. In...
Lilly commercial moves and tirzepatide momentum: retail pickup and blockbuster sales
Eli Lilly expanded distribution for its GLP‑1 tirzepatide obesity drug Zepbound by enabling retail pharmacy pick-up at Walmart through its LillyDirect platform, broadening access beyond home...
Diagnostics market expands: Guardant scales multi‑cancer blood screening as FDA clearances proliferate
Guardant Health launched its Shield multi‑cancer detection (MCD) test into broader clinical use and signaled plans to gather real‑world adoption data for multi-cancer screening, while Diasorin...
Funding and PE activity: Tubulis upsizes Series C; GHO Capital closes largest European healthcare PE fund
ADC developer Tubulis expanded its Series C to $401 million to accelerate proprietary antibody‑drug conjugate programs, reflecting investor appetite for differentiated oncology platforms....
Metsera M&A War: Novo Nordisk Counters Pfizer With $9B Bid
Novo Nordisk launched a surprise unsolicited bid for Metsera that outvalues Pfizer’s previously agreed acquisition, setting off a rapid escalation in the obesity M&A sweepstakes. Novo offered...
FDA Halts Intellia Phase‑3 CRISPR Trials: Liver Safety Signal
Regulators put two late‑stage clinical trials of Intellia Therapeutics’ CRISPR therapy nexiguran ziclumeran on formal hold after a participant developed severe liver injury, deepening scrutiny of...
Human kidney organoids scaled: Transplanted into perfused pig kidneys
Teams led by the Institute for Bioengineering of Catalonia and collaborators reported a reproducible, scalable method to generate thousands of human kidney organoids and successfully integrate...
Targeted immunotherapy advances: IL‑12 nanoparticles and myeloid resistance mechanisms
Two preclinical findings offer complementary routes to improve checkpoint immunotherapy. MIT engineers reported polymer‑coated nanoparticles that deliver IL‑12 directly into ovarian tumors; in...
AI accelerates discovery: Google finds drug lead; CZI and NVIDIA scale virtual cell models
AI is moving from hypothesis generation toward actionable biomedical outputs. Google announced a large foundation model that proposed a novel cancer drug combination which the company validated...
FDA deregulation push: Commissioner signals loosening; biosimilar trial rule proposed
Senior FDA leadership signaled further 'deregulatory' actions following recent steps to relax biosimilar clinical requirements, and the agency formally proposed removing mandatory clinical...
Illumina navigates China headwinds: flat Q3 but guidance nudged higher
Illumina reported flat third‑quarter revenues and slightly raised full‑year guidance while continuing to grapple with Chinese export restrictions that have depressed instrument sales. Management...
Lilly’s tirzepatide era: $10B quarter powers upgraded outlook
Eli Lilly disclosed blockbuster demand for tirzepatide, reporting about $10.1 billion in third‑quarter sales and raising its full‑year outlook as the medicine becomes the world’s top‑selling drug....